Results of a Phase 3 trial of the investigational drug revefenacin (TD-4208) for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD) demonstrated the therapy is well tolerated and is associated with a lower incidence of adverse side effects compared to standard of care with Boehringer Ingelheim’s…
Severe cases of chronic obstructive pulmonary disease (COPD) can lead to structural changes in the lungs. These changes not only aggravate lung function, they can also alter the bacterial community (microbiome) that reside in the lungs, according to the results of a study published in the journal PLOS ONE.
Sunovion Pharmaceuticals will divest its U.S. market rights for ciclesonide products for the treatment of asthma and allergic rhinitis to Covis Pharma. With this agreement, Sunovion confirms its focus on chronic obstructive pulmonary disease (COPD), and continued development of treatment options for this condition. Sunovion’s ciclesonide products (a type of…
Cytokinetics recently launched a Phase 1b clinical trial designed to evaluate the effect of CK-2127107 on physical function in older adults with limited mobility due to diseases associated with muscular weakness and/or fatigue, including chronic obstructive pulmonary disease (COPD). The therapeutic candidate is a next-generation fast skeletal muscle troponin activator…
Although studies show that continuous positive airway pressure (PAP) therapy can reduce hospitalizations among patients with chronic obstructive pulmonary disease (COPD), less than 8 percent of patients receive this treatment. PAP is a treatment delivered by a device that gently forces pressurized room air through the airways to keep the…
U.S. regulators have agreed to Sunovion Pharmaceuticals’ request for another review of its SUN-101/e-Flow system for treating chronic obstructive pulmonary disease. The review will cover a New Drug Application that Sunovion resubmitted after the Federal Drug Administration decided the company did not have to conduct additional clinical trials of SUN-101/e-Flow’s safety and effectiveness.
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…
The effects of vaporized cannabis on symptoms associated with chronic obstructive pulmonary disease (COPD) are the target of a new clinical trial that stems from a partnership between medical cannabis products company Tilray and the Research Institute of the McGill University…
Get regular updates to your inbox.